Study guide
4.1 Bias, Randomisation and Comparator Controls
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
4.1 Bias, Randomisation and Comparator Controls
Key Takeaways Explain This Topic AI
Allocation concealment prevents foreknowledge of the upcoming treatment assignment.
Blinding reduces bias from knowledge of treatment; the protocol should identify the blinded roles.
Intention-to-treat and per-protocol approaches have different purposes and possible biases.
Last updated: October 2026
Bias, Randomisation and Comparator Controls
In cluster randomization, entire social or organizational units (e.g., medical clinics, hospital wards, or geographical communities) are randomized rather than individual patients. This design is deployed when interventions cannot be easily restricted to individuals (e.g., hospital hygiene protocols, educational interventions) to avoid contamination between trial arms.
Bias Control Framework: Operationalizing ICH E9
Bias is any systematic tendency in design, conduct, analysis, or evaluation that causes trial estimates of a treatment effect to deviate systematically from the true value. ICH E9 outlines four primary operational biases and their counter-measures:
Bias Type Mechanism / Vulnerability Primary GCP Control Strategy
Selection Bias Systematic differences in baseline prognostic characteristics between treatment arms due to non-random allocation. Centralized, unpredictable, concealed randomization (e.g., interactive response technology).
Performance Bias Systematic differences in clinical care, co-interventions, or participant behavior driven by knowledge of treatment assignment. Double-blinding of participants, site staff, and treating physicians; standardized protocol care pathways.
Detection / Ascertainment Bias Systematic distortion in how clinical outcomes are evaluated, scored, or reported based on knowledge of assignment. Blinded Independent Central Review (BICR); blinded endpoint adjudication committees.
Attrition Bias Systematic differences in withdrawals, dropouts, or loss to follow-up leading to non-random missing data. Intention-to-Treat (ITT) principle; active patient retention strategies; comprehensive tracking of all randomized subjects.
Intention-to-Treat (ITT) vs. Per-Protocol (PP) Analysis
Intention-to-Treat (ITT): Analyzes all randomized subjects according to their assigned treatment group, regardless of whether they received the medication, adhered to the protocol, or dropped out early. The ITT principle helps preserve the prognostic balance created by randomization and estimates an effect consistent with the defined estimand.
Per-Protocol (PP): Restricts analysis only to subjects who completed the full prescribed course of therapy without major protocol deviations. While PP addresses an effect within a prespecified adherent subset, selection of a per-protocol subset can introduce bias because patients who drop out due to lack of efficacy or adverse events are excluded.
Randomization Methodologies & Allocation Concealment
Properly implemented concealed randomization reduces selection bias and establishes the theoretical foundation for statistical hypothesis testing.
Allocation Concealment: The critical procedural safeguard ensuring that investigators, research coordinators, and participants cannot foresee or decipher the upcoming treatment assignment prior to irreversible enrollment.
Centralized Interactive Response Technology (IRT): Interactive Voice/Web Response Systems (IVRS/IWRS) manage centralized randomization. Site staff enter validated eligibility criteria, and the IRT dynamically assigns a masked medication kit number, supporting allocation concealment when access, programming and site processes are controlled.
Blinding Levels & The Double-Dummy Technique
Blinding (masking) prevents performance bias and ascertainment bias.
Levels of Blinding
Open-Label: Both participant and site investigator are aware of treatment assignment. Used when blinding is physically impossible (e.g., surgical vs. medical management) or unnecessary.
Single-Blind: The term may refer to one blinded group; specify the actual blinded parties.
Double-Blind: Neither the participant nor the investigator/site clinical team knows the treatment assignment. The protocol should identify exactly which roles remain blinded.
Triple-Blind: The term can refer to several blinded roles; the protocol must define actual access and timing.
The Double-Dummy Technique
When comparing two active treatments that have visibly different pharmaceutical forms, administration routes, or dosing schedules (e.g., an oral tablet vs. a subcutaneous injection), masking cannot be achieved simply by packaging. A double-dummy design is deployed:
- Treatment Arm Oral Dosage Form Administered Subcutaneous Injection Administered
- Group A (Active Oral) Active Oral Tablet Matching Placebo Injection
- Group B (Active Injection) Matching Placebo Tablet Active Subcutaneous Injection
Every subject in both groups receives both an oral formulation and an injection, supporting masking; adverse effects or other clues can still create unblinding risks.
Control Groups and Comparative Hypotheses
Common control choices relevant to study design include the following; ACRP's reference list, rather than every related ICH guideline, defines the examination references:
Placebo Concurrent Control: Controls for the placebo effect, spontaneous disease remission, and observer bias. Highly sensitive for demonstrating assay superiority, but requiring ethical justification under the Declaration of Helsinki, with no exposure to additional serious or irreversible harm from withholding proven treatment.
Active Concurrent Control: Compares the investigational product to an established standard-of-care comparator.
Superiority Trial: Hypothesizes that the new agent is statistically and clinically superior to the active control.
Non-Inferiority Trial: Aims to show that the new agent is not clinically worse than the active control by more than a predefined, justified non-inferiority margin ( Δ \Delta Δ ). Often utilized when the new agent offers non-efficacy advantages, such as superior safety, reduced dosing frequency, or oral instead of intravenous administration.
Historical (External) Controls: Compares trial participants to patients treated outside the study in the past. Highly vulnerable to severe selection bias, temporal shifts in medical care, and differing diagnostic criteria; requiring careful justification of comparability and bias controls.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9 , ICH E9(R1) , ICH E8(R1) .